11/30
03:20 pm
wgs
HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Low
Report
HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
11/6
08:00 am
wgs
GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting
Low
Report
GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting
11/4
11:33 am
wgs
Artificial Intelligence Powered Rare Disease Diagnosis Research Report 2025: Market to Surpass $5.5 Billion by 2029 on Accelerated Adoption of Predictive and Personalized Healthcare - Forecast to 2034 [Yahoo! Finance]
Low
Report
Artificial Intelligence Powered Rare Disease Diagnosis Research Report 2025: Market to Surpass $5.5 Billion by 2029 on Accelerated Adoption of Predictive and Personalized Healthcare - Forecast to 2034 [Yahoo! Finance]
11/4
11:05 am
wgs
GeneDx (NASDAQ:WGS) had its price target raised by analysts at Wells Fargo & Company from $95.00 to $140.00. They now have an "equal weight" rating on the stock.
Low
Report
GeneDx (NASDAQ:WGS) had its price target raised by analysts at Wells Fargo & Company from $95.00 to $140.00. They now have an "equal weight" rating on the stock.
11/4
08:00 am
wgs
GeneDx to Participate in Upcoming Investor Conferences
Medium
Report
GeneDx to Participate in Upcoming Investor Conferences
11/1
01:05 am
wgs
Low
Report
10/29
10:08 am
wgs
GeneDx (NASDAQ:WGS) was given a new $160.00 price target on by analysts at Canaccord Genuity Group Inc..
Medium
Report
GeneDx (NASDAQ:WGS) was given a new $160.00 price target on by analysts at Canaccord Genuity Group Inc..
10/29
08:08 am
wgs
GeneDx (NASDAQ:WGS) had its price target raised by analysts at BTIG Research from $140.00 to $165.00. They now have a "buy" rating on the stock.
Medium
Report
GeneDx (NASDAQ:WGS) had its price target raised by analysts at BTIG Research from $140.00 to $165.00. They now have a "buy" rating on the stock.
10/29
07:19 am
wgs
GeneDx (NASDAQ:WGS) had its "buy" rating reaffirmed by analysts at Guggenheim.
Medium
Report
GeneDx (NASDAQ:WGS) had its "buy" rating reaffirmed by analysts at Guggenheim.
10/28
06:30 am
wgs
GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
Low
Report
GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
10/27
08:00 am
wgs
GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims
Low
Report
GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims
10/24
09:40 am
wgs
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights
10/22
12:24 pm
wgs
GeneDx (NASDAQ:WGS) was upgraded by analysts at Canaccord Genuity Group Inc. to a "strong-buy" rating.
Low
Report
GeneDx (NASDAQ:WGS) was upgraded by analysts at Canaccord Genuity Group Inc. to a "strong-buy" rating.
10/22
08:34 am
wgs
GeneDx (NASDAQ:WGS) had its price target raised by analysts at BTIG Research from $125.00 to $140.00. They now have a "buy" rating on the stock.
Low
Report
GeneDx (NASDAQ:WGS) had its price target raised by analysts at BTIG Research from $125.00 to $140.00. They now have a "buy" rating on the stock.
10/22
08:00 am
wgs
GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025
Low
Report
GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025
10/20
08:05 am
wgs
GeneDx (NASDAQ:WGS) was given a new $155.00 price target on by analysts at Canaccord Genuity Group Inc..
Medium
Report
GeneDx (NASDAQ:WGS) was given a new $155.00 price target on by analysts at Canaccord Genuity Group Inc..
10/20
08:00 am
wgs
GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing
Medium
Report
GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing
10/14
08:00 am
wgs
GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer
Medium
Report
GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer
10/13
08:00 am
wgs
GeneDx to Partner with Florida’s Sunshine Genetics Network, Launching Nation’s First State-Backed Genomic Newborn Screening Program
Medium
Report
GeneDx to Partner with Florida’s Sunshine Genetics Network, Launching Nation’s First State-Backed Genomic Newborn Screening Program
10/9
08:00 am
wgs
GeneDx to Launch Autism Partnership Program to Expand Access to Exome and Genome Testing, including Dedicated SHANK3 Program
Medium
Report
GeneDx to Launch Autism Partnership Program to Expand Access to Exome and Genome Testing, including Dedicated SHANK3 Program
10/8
08:00 am
wgs
GeneDx to Showcase Pioneering Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
Low
Report
GeneDx to Showcase Pioneering Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
10/7
08:00 am
wgs
GeneDx to Report Third Quarter 2025 Financial Results on Tuesday, October 28, 2025
Low
Report
GeneDx to Report Third Quarter 2025 Financial Results on Tuesday, October 28, 2025
10/4
05:46 am
wgs
GeneDx (NASDAQ:WGS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
GeneDx (NASDAQ:WGS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
10/1
04:01 pm
wgs
GeneDx Announces First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award
Low
Report
GeneDx Announces First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award
9/30
08:00 am
wgs
GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth
Medium
Report
GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth